Faeth Therapeutics, Inc. (FTH) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $2.00K; Additional Paid in Capital, Common StockUSD $642.40M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-63.00K; Retained Earnings (Accumulated Deficit)USD $-469.38M.
- 2026-03-31: Common Stock, Value, IssuedUSD $0.00; Additional Paid in Capital, Common StockUSD $316.11M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-24.00K; Retained Earnings (Accumulated Deficit)USD $-453.37M.
- 2025-12-31: Common Stock, Value, IssuedUSD $0.00; Additional Paid in Capital, Common StockUSD $301.73M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $1.00K; Retained Earnings (Accumulated Deficit)USD $-283.14M.
- 2025-09-30: Common Stock, Value, IssuedUSD $0.00; Additional Paid in Capital, Common StockUSD $301.43M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-3.00K; Retained Earnings (Accumulated Deficit)USD $-278.42M.
Faeth Therapeutics, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2.00K | $642.40M | $-63.00K | $-469.38M | $172.96M | 3 month · $4.48M |
| 2026-03-31 | $0.00 | $316.11M | $-24.00K | $-453.37M | $-137.29M | 3 month · $12.90M |
| 2025-12-31 | $0.00 | $301.73M | $1.00K | $-283.14M | $18.59M | 12 month · $1.27M |
| 2025-09-30 | $0.00 | $301.43M | $-3.00K | $-278.42M | $23.01M | 3 month · $254.00K |
| 2025-06-30 | $0.00 | $301.18M | $-11.00K | $-273.85M | $27.31M | 3 month · $264.00K |
| 2025-03-31 | $3.00K | $300.91M | $-6.00K | $-268.92M | $31.99M | 3 month · $461.00K |
| 2024-12-31 | $0.00 | $300.45M | $-13.00K | $-262.05M | $38.39M | 12 month · $3.13M |
| 2024-09-30 | $3.00K | $300.04M | $14.00K | $-254.28M | $45.78M | 3 month · $733.00K |
| 2024-06-30 | $3.00K | $299.31M | $-93.00K | $-247.03M | $52.19M | 3 month · $795.00K |
| 2024-03-31 | $3.00K | $298.50M | $-137.00K | $-239.89M | $58.47M | 3 month · $1.22M |
| 2023-12-31 | $3.00K | $297.00M | $-209.00K | $-231.90M | $64.89M | 12 month · $4.45M |
| 2023-09-30 | $2.00K | $295.88M | $-402.00K | $-224.48M | $71.00M | 3 month · $1.05M |
| 2023-06-30 | $3.00K | $297.10M | $-549.00K | $-217.36M | $79.20M | 3 month · $1.09M |
| 2023-03-31 | $3.00K | $303.64M | $-823.00K | $-207.97M | $94.85M | 3 month · $1.21M |
| 2022-12-31 | $3.00K | $302.20M | $-1.00M | $-197.79M | $103.41M | 12 month · $5.78M |
| 2022-09-30 | $3.00K | $300.75M | $-1.21M | $-185.56M | $113.99M | 3 month · $1.48M |
| 2022-06-30 | $3.00K | $299.27M | $-1.21M | $-172.15M | $125.92M | 3 month · $1.40M |
| 2022-03-31 | $3.00K | $297.81M | $-899.00K | $-161.61M | $135.31M | 3 month · $1.51M |
| 2021-12-31 | $3.00K | $296.05M | $-333.00K | $-149.21M | $146.51M | 12 month · $5.66M |
| 2021-09-30 | $3.00K | $295.11M | $-69.00K | $-139.84M | $155.21M | 3 month · $1.74M |
| 2021-06-30 | $3.00K | $293.38M | $-101.00K | $-130.16M | $163.12M | 3 month · $1.75M |
| 2021-03-31 | $3.00K | $291.63M | (m) | $-120.38M | $171.25M | 3 month · $1.35M |
| 2020-12-31 | (m) | $55.97M | (m) | $-112.41M | $-56.44M | 12 month · $1.49M |
| 2020-09-30 | (m) | (m) | (m) | (m) | $-51.68M | 3 month · $781.00K |
| 2020-06-30 | (m) | (m) | (m) | (m) | $-47.09M | 3 month · $163.00K |
| 2020-03-31 | (m) | (m) | (m) | (m) | $-42.89M | 3 month · $194.00K |
| 2019-12-31 | (m) | (m) | (m) | (m) | $-68.66M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |